Organic Active Ingredients TRIZ Cases

Fagopyrum dibotyo extract and flavonoid dimers inhibit viral entry into intestinal epithelial cells, addressing the lack of norovirus antivirals.

Diluting honey to 2-50% w/w reduces viscosity and stinging sensation, resolving the contradiction between ease of administration and product stability.

Converts THCA-A to Δ9-THC through staged heating, then extracts the compound using pressurized liquid bonding to eliminate toxic solvent risks.

A topical ointment containing a specific JAK inhibitor compound promotes hair regrowth in alopecia areata patients.

Benzothiadiazepine derivatives address limited efficacy of existing compounds by enhancing pharmacological activity through specific structural modifications.

Replacing alpha-tocopherol with beta, gamma, and delta isoforms enhances oligosaccharide assimilation efficiency by bifidobacteria.

Antisense polynucleotide agents bind to PNPLA3 mRNA to inhibit gene expression and reduce triglyceride accumulation in the liver.

Optimized glass composition prevents particulate shedding in pharmaceutical solutions while maintaining chemical stability.

Galactose-modified dextran sulfate binds blood LDL and directs the complex to hepatocytes for decomposition, avoiding invasive apheresis procedures.

Heterocyclic derivatives selectively block Nav1.7 and Nav1.8 channels to treat pain while avoiding cardiac side effects from Nav1.5 inhibition.

Pyrazole derivatives with tailored substituents target TAAR1 receptors, reducing side effects from adrenergic binding.

Targeting PLA2G5 reduces intravascular hemolysis severity, preventing lipid dysbiosis and lowering mortality associated with sepsis.

Formula I fused bicyclic compounds inhibit MET, ALK, and RON kinases to treat cancers while maintaining oral bioavailability.

Abl kinase inhibitors reduce axon overgrowth by targeting Dscam pathways, improving therapeutic effectiveness while minimizing cancer risk.

Combining sebacoyl dinalbuphine with acetaminophen creates a synergistic analgesic formulation.

Demethylating agents reverse hypermethylation of effector gene promoters to restore cytokine production and cytotoxic activity during chronic antigen exposure.

Nicotine and pilocarpine compositions reduce oral cancer risk by managing withdrawal symptoms without triggering nicotinic receptors.

Modular isoquinoline compounds inhibit Wnt signaling and DYRK1A to treat disorders with aberrant cellular proliferation.

Radical coupling of flavonoids in mild aqueous media eliminates toxic heavy metal catalysts while enabling high-yield synthesis.

Micronized Compound A with D90 ≤ 20 µm inhibits FGFR1 and KDR to overcome chemotherapy resistance in advanced neuroendocrine tumors.

A pharmaceutical composition containing poly-gamma-glutamic acid and aspartame stimulates the immune system to treat cervical intraepithelial neoplasia.

Hydrogel entrapping solid lipid matrix particles releases local anesthetics in a biphasic manner for sustained surgical analgesia.

Dual-layer nalbuphine tablets combine immediate and sustained release to maintain therapeutic blood levels while reducing dosing frequency.

Strategic high dose vitamin D regimens reduce pulmonary inflammation and mean pulmonary artery pressure while accelerating epithelial tissue regeneration.

An oral care composition alters biofilm composition to reduce harmful microorganisms while increasing health-promoting species.

Aqueous extraction isolates specific glucuronide compounds from Glechoma longituba to inhibit DPP4 enzyme activity, reducing blood glucose levels.

A methacrylic resin ink composition reduces offset and sticking in printing.

Monitoring pERK expression levels guides naltrexone dosage adjustments, resolving the trade-off between therapeutic efficacy and immune suppression.

6-Azaindole compounds inhibit Toll-like receptor 7, 8, and 9 signaling to treat autoimmune diseases with improved stability.

A STAT5 antagonist downregulates HIF 2a to eliminate residual cancer stem cells after initial tyrosine kinase inhibitor treatment.

Merges IAP inhibitors with immune checkpoint modulators to overcome drug resistance and inhibit metastasis.

A marine algal glycoprotein medicament treats fatty liver, hepatitis, and cirrhosis.

T151742 aurone derivatives specifically inhibit ERO1α activity, addressing resistance in non-small cell lung cancer treatments.

Replacing phenylsulfonamide groups with sulfoximines eliminates carbonic anhydrase inhibition side effects while maintaining potent tumor growth suppression.

Cepharanthine blocks the HLA-DR3 antigen binding pocket, preventing autoimmune attacks on pancreatic beta cells while minimizing global immune suppression.

GHSR1a antagonists block ghrelin signaling to reduce proteasome-mediated muscle degradation and improve endurance in sarcopenia.

Bifunctional compounds recruit the ubiquitin/proteasome system to degrade target enzymes.

Segmentation and local quality principles guide the design of a specific siRNA precursor that inhibits K-RAS expression to treat resistant tumors.

Novel 2,3-dihydro-furo[2,3-c]pyridine derivatives activate GPR119 receptors to stimulate insulin secretion and improve beta cell function.

Buchwald cross-coupling replaces hydrazine to synthesize the triazolopyrimidine gamma-secretase modulator without column purification.

A tiotropium metered dose inhaler composition uses a silane primer and fluorinated canister lining to prevent drug adsorption.

A Chk-1 inhibitor synthesis route uses crystalline intermediates to replace chromatography and reduce reaction steps.

Modified purine nucleotides overcome toxicity and mutation risks by acting as intermediaries that inhibit viral replication.

Segmented biodegradable polymer matrices release paclitaxel gradually to maintain effective vessel wall concentrations, reducing systemic dosage requirements.

Simultaneous inhibition of GST-π and RB1CC1 enhances apoptosis while reducing side effects from normal cell suppression.

Segmenting hydrophilic polymers into low and high molecular weight components resolves the contradiction between rapid API release and abuse deterrent strength.

Leucine replaces phospholipids to maintain dispersibility while improving chemical stability against moisture.

Crystalline folate salts combine tetrahydrofolic acid anions with organic alkanolamine cations to form stable pharmaceutical compounds.

Combining a Pdia4 inhibitor with insulin sensitizers reverses type 2 diabetes by restoring beta-cell sustainability.

Gonadal organoids rebalance the hypothalamic-pituitary-gonadal axis while avoiding neoplasia risks associated with supplemental hormone addition.

Periodic high loading doses suppress bacterial resistance while moderate maintenance doses prevent nausea.

A PEG-R9 peptide complex delivers siRNA via electrostatic binding to form stable nano-sized assemblies.

Whole plant Lilium candidum extracts combined with polyunsaturated fatty acids reduce cytotoxicity while inhibiting UVB-induced melanogenesis.

A pharmaceutical combination of flavonoids and sphingosine-1-phosphate lyase inhibitors reduces neutrophil influx.

Local delivery of a sustained release formulation reduces fibroid volume and side effects by minimizing uncontrolled drug diffusion.

Merges ERK1/2 and SHP2 inhibitors to overcome resistance in solid tumors.

Optimized dextran sulfate parameters resolve the contradiction between biological efficacy and toxicity to treat IBMIR.

Quinazolinone analogs treat flavivirus infections by targeting Hepatitis C and Japanese Encephalitis viruses via segmented structural optimization.

An HDAC6 inhibitor reduces cyst growth by modulating cholangiocyte proliferation and beta-catenin levels.

Segmented lumens and an anchor balloon enable stable portal venous access, bypassing systemic circulation to reduce side effects during hepatic therapy.

Pyrrolidin-3-ylacetic acid derivatives inhibit the fractalkine-CX3CR1 pathway to treat inflammatory bowel disease.

Segmenting the enzyme active site and modifying chemical parameters creates targeted therapies that reduce liver steatosis.

Azaindazole compounds antagonize Wnt pathway activity, addressing the lack of effective inhibitors for disorders characterized by aberrant signaling.

Modulating endothelial proteins ETRB, ET-1, and ICAM-1 increases T cell infiltration into solid tumors, resolving inadequate immune response.

Excess adenylated ligase with optimized manganese and pH ensures consistent circularization yields across variable ssDNA sequences.

Ergothioneine extends lifespan by modulating FOXO pathways, addressing the healthcare burden of age-related diseases.

Novel quinoline derivatives suppress TLR7 and TLR8 pathways to control systemic lupus erythematosus while reducing dose-limiting side effects.

Thiophene-phenothiazine compounds fuse thiophene to phenothiazine scaffolds to generate reactive oxygen species under red light.

Segmented PROTAC molecules recruit E3 ligase cereblon to degrade IRAK4, overcoming limited efficacy of traditional kinase inhibitors.

Administering soy protein and vitamin C reduces elevated 4-ethylphenyl sulfate levels, alleviating canine anxiety and stress symptoms.

KPT-251 blocks XPO1-mediated export of Hsp70, preventing GATA-1 cleavage and restoring erythroid maturation in myelodysplastic syndrome.

Sulfamide compounds halt epileptogenesis progression, reducing long-term medication needs and side effects.

siRNA and MHC class I delivery protects motor neurons from astrocyte toxicity by silencing perforin and granzyme B expression.

A phenyldifluoromethyl-substituted prolinamide compound inhibits cathepsin S enzyme activity.

Pharmaceutical salts of a phthalazine-based PARP inhibitor enhance solubility and bioavailability to overcome DNA repair resistance in tumor cells.

Senicapoc inhibits KCa3.1 channels to reduce neuroinflammation, extending stroke treatment beyond narrow windows.

Peptide-based FAPIN nanoparticles achieve 100% drug loading and real-time imaging, eliminating non-pharmaceutical carrier toxicity.

Porous extraction tablets capture analytes from liquid samples using molecularly imprinted polymers, reducing sample volume requirements and extraction time.

Combination therapy merges CK2 inhibitors with immune checkpoint blockers to boost T cell infiltration, overcoming moderate single-agent efficacy.

Antisense oligonucleotides bind complementary microRNA strands, suppressing oncogenic activity that conventional treatments fail to inhibit.

Dual-targeting CD73 and HER2 reduces toxicity while maximizing therapeutic efficacy against gastric adenocarcinoma.

Purinergic receptor inhibitors block bitter taste signals, improving pediatric medication compliance without harmful additives.

Fatty acid mediators mask capsaicin pungency, improving patient compliance while maintaining therapeutic efficacy.

A spray-drying process produces purified LNT and LNnT powder from aqueous solutions.

Lepimectin potentiates chloride ion permeability to induce neuromuscular hyperpolarization, reducing side effects from conventional rosacea therapies.

Novel pyrimido naphthyridine compounds inhibit protein kinase CK2 activity to deliver potent anticancer effects across multiple cell lines.

Wet milling diroximel fumarate particles reduces cohesion and narrows size distribution, resolving dry milling compaction inconsistencies.

Crosslinked chondroitin sulfate particles encapsulate antibiotics to reduce toxicity and administration frequency in ocular infection treatment.

Replacing the triphosphate group with a hydroxy group activates interferon-beta and ISG56, inducing tumor cell death while sparing normal cells.

A photodynamic therapy method applies aminolevulinic acid and delays light exposure to localize protoporphyrin IX in acne lesions.

A composite probiotic powder combines multiple bacterial strains with prebiotics to enhance gut microbiota diversity.

A closed-circuit liposome production system uses laser transmittance measurement to regulate particle diameter without physical sampling.

Intracystic injection of antineoplastic particles reduces cyst volume and growth rate, addressing low resolution rates from ethanol lavage.

Substituted benzimidazoles inhibit bromodomains by binding acetylated lysine residues, resolving inadequate therapeutic impact in cancer treatment.

Thieno[2,3-d]pyrimidinone structures modulate AMPA receptors to enhance synaptic responses while reducing neurotoxic side effects.

Hydroxypropyl methylcellulose stabilizes ethosuximide in pure water, eliminating co-solvent toxicity and adverse effects in pediatric patients.

Unsymmetrical pyrrolobenzodiazepine dimers form sequence-selective DNA lesions to resolve synthesis complexity and biological activity trade-offs.